Vivos Inc. (USOTC:RDGL) has announced plans to expand its IsoPet Animal Cancer Division through four additional veterinary facilities across the United States, extending the potential reach of its targeted radiation therapy for animals with cancer.
The medical device company said veterinary clinics in Kentucky, North Carolina, California and Florida are progressing through the certification, licensing and onboarding procedures required to administer IsoPet treatments.
The expansion forms part of Vivos’ strategy to increase access to its Precision Radionuclide Therapy (PRnT) technology while developing a larger network of veterinary treatment centres capable of supporting recurring product sales.
The company expects the additional facilities to increase treatment capacity and create opportunities for revenue growth once they complete the necessary regulatory and operational requirements.
Which Four Veterinary Clinics Are Joining the IsoPet Network?
Vivos identified four veterinary facilities currently advancing towards IsoPet certification, covering different geographic markets and veterinary specialties.
Veterinary Specialist Partners, based in Louisville, Kentucky, is a specialty veterinary hospital led by co-founders Dr. Grace Clark and Dr. Scott Rizzo. Both are veterinary specialists and Diplomates of the American College of Veterinary Internal Medicine.
The hospital provides advanced diagnostic services, internal medicine and oncology care. Adding IsoPet would expand its available treatment options for companion animals diagnosed with cancer.
Grace Veterinary Hospital in Sherrills Ford, North Carolina, is also progressing through the onboarding process.
Led by Dr. Jean Tuttle, the facility provides veterinary medicine, rehabilitation and patient-focused care. Its participation would introduce an additional localised cancer treatment option for pets in North Carolina and surrounding areas.
Malibu Coast Animal Hospital in Malibu, California, is advancing through the state’s radioactive materials licensing process.
Founded by Dr. Dean Graulich, the practice offers medical and surgical veterinary services. If certification is completed, it would become Vivos’ first IsoPet-certified clinic in California.
The fourth facility, Palm Beach Equine Clinic in Wellington, Florida, is preparing for IsoPet certification.
Led by board-certified equine surgeon Dr. Robert Brusie, the clinic specialises in advanced equine medicine and surgery. Its participation would expand the potential use of IsoPet in treating horses with solid tumours and other localised cancers.
All four facilities remain at various stages of the approval and preparation process, and Vivos has not announced dates for their first IsoPet treatments.
What Is IsoPet and How Does the Cancer Treatment Work?
IsoPet is a veterinary cancer treatment developed by Vivos using its Precision Radionuclide Therapy technology.
The treatment uses Yttrium-90, a therapeutic radioisotope, to deliver radiation directly to cancerous tumours.
The technology is designed to provide localised radiation treatment rather than relying on broader radiation exposure.
IsoPet is commercially available for veterinary use through appropriately licensed and certified facilities in the United States.
Vivos is developing the treatment as part of its wider radionuclide therapy platform, which also includes RadioGel, a product being developed for human cancer treatment.
The company is seeking to expand the veterinary application of IsoPet by establishing additional treatment locations and increasing the number of animals that can access the therapy.
The latest announcement did not provide new clinical efficacy data or results from animals treated with IsoPet.
Why Does Each Veterinary Clinic Need Special Certification?
Unlike conventional veterinary treatment services, IsoPet requires participating facilities to satisfy regulatory requirements governing the use of radioactive materials.
Because the therapy uses Yttrium-90, veterinary hospitals must obtain the appropriate radioactive materials licences before administering treatments.
Licensing requirements vary between states, and the review and approval process can take different amounts of time depending on the jurisdiction.
Vivos has also developed a structured certification programme intended to prepare veterinary teams for the administration of IsoPet.
The process includes radiation safety education, training in treatment protocols, equipment preparation and practical exercises.
The company also provides support during a facility’s initial treatments to help establish consistent procedures.
These requirements are intended to ensure that veterinary teams can administer the therapy safely and in accordance with applicable regulations.
Vivos said the certification process takes time but is necessary to establish sustainable treatment centres capable of supporting ongoing commercial activity.
Why Is the California Clinic Important for Vivos?
Malibu Coast Animal Hospital could become Vivos’ first IsoPet-certified veterinary facility in California.
The hospital is currently working through the state’s radioactive materials licensing process.
Successful completion would establish an IsoPet treatment location on the US West Coast, expanding the company’s geographic coverage.
California represents an additional market for Vivos as it seeks to make its veterinary cancer therapy accessible across more regions.
The company believes that expanding its network geographically can help increase treatment opportunities and support future product demand.
However, the Malibu facility has not yet completed certification, and Vivos has not disclosed a timetable for regulatory approval.
The announcement also did not provide projected treatment volumes or revenue expectations for the proposed California location.
How Could the Florida Clinic Expand IsoPet Into Equine Oncology?
Palm Beach Equine Clinic in Wellington, Florida, represents an opportunity for Vivos to broaden the application of IsoPet within equine veterinary medicine.
The facility specialises in the treatment of horses and provides advanced medical and surgical services.
Led by Dr. Robert Brusie, the clinic is progressing through preparations for IsoPet certification.
Its participation could provide an additional treatment option for horses diagnosed with solid tumours and other localised cancers.
The potential addition of an equine specialist also demonstrates Vivos’ interest in extending IsoPet beyond companion animal treatment.
By developing relationships with veterinary facilities serving different animal populations, the company aims to broaden the commercial applications of its technology.
However, the announcement did not disclose any confirmed equine treatments or expected patient numbers at the Florida facility.
How Could Four New Clinics Increase IsoPet Revenue?
Vivos views the expansion of its veterinary treatment network as an important component of its commercial growth strategy.
Each certified clinic has the potential to become a recurring customer for IsoPet products as it establishes an ongoing treatment programme.
The company expects additional facilities to increase treatment capacity and provide greater geographic access for veterinary patients.
As treatment volumes rise, Vivos anticipates corresponding opportunities for increased product sales.
The company also reported growing demand across its existing certified clinic network, as more pet owners seek IsoPet treatment for their animals.
Management believes this demand supports further investment in expanding the number of participating veterinary facilities.
However, the four newly announced clinics have not yet completed all certification and licensing requirements.
Consequently, their potential revenue contributions will depend on successful onboarding, regulatory approvals and subsequent patient treatment activity.
Vivos did not provide specific revenue projections for the additional locations.
What Role Does Vivos’ Washington Manufacturing Facility Play?
Vivos has established domestic IsoPet manufacturing capabilities at its Applied Process Engineering Laboratory (APEL) in Richland, Washington.
The facility supports production of the company’s radionuclide therapy products for veterinary applications.
APEL forms part of the infrastructure Vivos is developing to support an expanding network of certified treatment centres.
As additional clinics begin offering IsoPet, the company expects its manufacturing capabilities to support increased product demand.
Vivos is also working to reduce production costs at the facility.
Management has identified cost reduction as an important objective in its efforts to move towards break-even operations and eventual profitability.
The company did not disclose current production volumes, manufacturing costs or specific cost-saving targets in the latest announcement.
Nevertheless, the combination of domestic production capacity and a growing veterinary clinic network forms part of its longer-term commercial strategy.
How Is Vivos Building a Scalable Veterinary Cancer Treatment Business?
Vivos is seeking to establish IsoPet as a recurring revenue-generating business through a network of appropriately licensed veterinary facilities.
The company’s approach involves identifying suitable veterinary partners, supporting them through regulatory licensing and providing specialised training.
Once certified, participating clinics can begin administering IsoPet treatments and potentially generate ongoing demand for the company’s products.
This model allows Vivos to expand its commercial reach through established veterinary hospitals rather than developing and operating its own treatment facilities.
The four additional clinics represent potential expansion into different regions and veterinary specialties.
Vivos is also focused on increasing utilisation at existing certified facilities.
The company believes that converting its clinic pipeline into operational treatment centres will be important to achieving sustainable revenue growth.
However, the pace of expansion remains dependent on regulatory approval timelines, clinical readiness and the ability of participating facilities to establish treatment programmes.
What Does the Expansion Mean for Vivos’ Broader Cancer Treatment Strategy?
The IsoPet expansion supports Vivos’ wider development of Precision Radionuclide Therapy technology.
The company is pursuing applications for its Yttrium-90-based treatment platform in both veterinary and human oncology.
IsoPet is its commercially available veterinary product, while RadioGel is being developed for human cancer treatment.
By expanding the IsoPet network, Vivos aims to strengthen its commercial operations and generate additional revenue from veterinary applications.
The company is also developing the manufacturing and operational infrastructure needed to support greater treatment activity.
The latest announcement focuses on veterinary clinic expansion and does not provide new information about the regulatory development or clinical progress of RadioGel for human use.
The commercial performance of IsoPet will therefore remain a separate consideration from the development of the company’s human oncology programme.
Outlook: What Should Investors Watch Next?
Vivos’ announcement of four additional veterinary facilities represents another step in the expansion of its IsoPet Animal Cancer Division.
The prospective locations in Kentucky, North Carolina, California and Florida would extend the company’s treatment network across multiple US regions.
The potential addition of its first California clinic would establish a presence on the West Coast, while the Florida facility could expand opportunities in equine oncology.
However, the clinics remain in the certification, licensing or onboarding stages and have not yet been confirmed as fully operational IsoPet treatment centres.
Investors will be monitoring their progress towards certification, the timing of initial treatments and the extent to which additional facilities contribute to recurring product demand.
The company is also seeking to increase utilisation across its existing clinic network while reducing production costs at its Washington manufacturing facility.
Vivos’ ability to convert its expanding clinic pipeline into operational treatment centres and sustained product sales will be important in assessing the commercial development of its veterinary cancer business.
More About Vivos Inc.
Vivos Inc. is a medical device company developing targeted cancer treatments based on Yttrium-90 radionuclide technology.
Its Precision Radionuclide Therapy platform is designed to deliver therapeutic radiation directly to cancerous tumours.
The company’s two principal treatment programmes are IsoPet, developed for veterinary oncology, and RadioGel, which is being developed for human cancer treatment.
IsoPet is commercially available for veterinary use through appropriately licensed and certified facilities in the United States.
Vivos is expanding its veterinary treatment network while developing domestic manufacturing capabilities at its Applied Process Engineering Laboratory in Richland, Washington.
The company aims to increase access to its technology, support recurring commercial revenue and advance its broader cancer treatment platform.